Metraipolis › archive › dc_d2d205ec3c50

Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma — Europe PMC PMID:40536814

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40536814
DOI
10.1172/jci181893
License (as archived)
solo-consultazione
Archived
2026-11-10T14:38:51.800Z
SHA-256 of the archived text
37cc58b134a771a939de33fbc85113e29ed8671a547c67585004bd5451f7d503
Stable URL of this page
https://metraipolis.com/documento/dc_d2d205ec3c50

How to cite

Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma — Europe PMC PMID:40536814 — Europe PMC (en), https://europepmc.org/article/MED/40536814 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d2d205ec3c50 (Metraipolis archive dc_d2d205ec3c50, sha256 37cc58b134a771a939de33fbc85113e29ed8671a547c67585004bd5451f7d503)
BibTeX
@misc{dcd2d205ec3c50,
  title = {Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma — Europe PMC PMID:40536814},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40536814},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d2d205ec3c50; sha256 37cc58b134a771a939de33fbc85113e29ed8671a547c67585004bd5451f7d503},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40536814. Agents can read the archived copy with the MCP tool read_document.